Up 24% in a month! This ASX biotech share is hitting a record high on trial update

The SECuRE trial is getting investors excited. Here's the latest.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clarity Pharmaceuticals Ltd (ASX: CU6) shares are scaling new heights on Thursday.

In morning trade, the ASX biotech share climbed 4% to a new record high of $7.67.

This means its shares are now up 24% since this time last month.

Why is this ASX biotech share breaking records?

Investors have been buying this clinical stage radiopharmaceutical company's following the release of an update on its SECuRE trial.

The SECuRE trial is a Phase I/IIa theranostic trial for the identification and treatment of participants with prostate-specific membrane antigen (PSMA)-expressing metastatic castrate-resistant prostate cancer (mCRPC) using 64Cu/67Cu-SAR-bisPSMA.

64Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent 67Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 44 participants in the US and Australia.

The overall aim of the trial is to determine the safety and efficacy of 67Cu-SAR-bisPSMA for the treatment of prostate cancer.

What was today's update?

According to the release, a safety review has been undertaken for the first three participants enrolled in cohort 4 of the SECuRE trial who received two doses of 67Cu-SAR-bisPSMA.

Two of these participants have completed the dose limiting toxicity (DLT) period and one will complete the DLT period by the end of September. Importantly, no DLTs were observed to date, which is in line with cohorts 1, 2 and 3.

Furthermore, the safety profile of multiple doses of 67Cu-SAR-bisPSMA remains positive, with almost all adverse events (AEs) being mild or moderate. In addition, almost all AEs have either resolved or improved at the last assessment.

The preliminary efficacy assessment from cohort 4 after two therapy cycles in two participants has also been positive. Following completion of the DLT period, it showed that both participants exhibited greater than 60% drops in prostate-specific antigen (PSA) levels in weeks following their second dose.

The ASX biotech's executive chair, Dr Alan Taylor, was pleased with the impressive results. He said:

The results from the SECuRE trial continue to impress, with the data from all 3 participants in cohort 4 exhibiting an excellent safety profile for 67Cu-SAR-bisPSMA, following 2 cycles of the product at the highest dose of 12GBq. The early approval by the SRC to progress with the trial and the excellent safety data to date reinforce our confidence that 67Cu-SAR-bisPSMA has a favourable safety profile as we consider the dosing schedule for the next phase of the trial.

Although safety is our priority during this dose escalation phase, the efficacy data continues to be outstanding, with both participants who have thus far completed the DLT period analysis exhibiting an excellent response to treatment even at these early time points. […] The data from all cohorts is now presenting a unique proposition of a great safety profile coupled with remarkable efficacy, even in patients who had failed so many previous lines of therapy.

Should you invest $1,000 in Clarity Pharmaceuticals right now?

Before you buy Clarity Pharmaceuticals shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Clarity Pharmaceuticals wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

With a projected 7% dividend yield, is the Medibank share price a buy?

Investors may receive very healthy dividends from this stock.

Read more »

Healthcare Shares

Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Goldman Sachs tips ResMed shares to rocket 30% to a record high

The broker is feeling very bullish about the sleep disorder treatment company.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Healthcare Shares

Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

The market didn't like what this stock had to say this morning...

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

ResMed shares are up 42% in a year. This shows why they could still be great value

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025.

Read more »